Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Cyclobenzaprine
Drug ID BADD_D00545
Description Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961[A185039] and has been available for human use since 1977.[A184982] It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
Indications and Usage For use as an adjunct to rest and physical therapy for relief of muscle spasm associated with acute, painful musculoskeletal conditions.
Marketing Status Prescription; Discontinued
ATC Code M03BX08
DrugBank ID DB00924
KEGG ID D07758
MeSH ID C004704
PubChem ID 2895
TTD Drug ID D01KHH
NDC Product Code 68071-3150; 63187-812; 0615-8084; 61919-305; 69097-845; 69097-846; 51927-0118; 70518-0635; 58118-0846; 53002-3080; 53002-0521; 67296-1728; 70518-3159; 68071-3154; 60687-558; 50090-3253; 70934-005; 70518-0082
Synonyms cyclobenzaprine | Flexeril | Lisseril | cyclobenzaprine hydrochloride
Chemical Information
Molecular Formula C20H21N
CAS Registry Number 303-53-7
SMILES CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Thirst14.03.02.007; 08.01.09.021--Not Available
Thrombocytopenia01.08.01.002--Not Available
Tinnitus17.04.07.004; 04.04.01.002--
Tongue coated07.14.02.011--Not Available
Tongue discolouration07.14.02.006--Not Available
Tongue disorder07.14.01.002--Not Available
Tongue oedema23.04.01.009; 10.01.05.008; 07.14.02.007--Not Available
Tremor17.01.06.002--
Unresponsive to stimuli17.02.05.0310.000230%Not Available
Upper respiratory tract infection22.07.03.011; 11.01.13.009--
Urinary retention20.02.02.0110.000098%
Urticaria23.04.02.001; 10.01.06.0010.000197%
Vascular purpura23.06.01.008; 01.01.04.007; 24.07.06.011--Not Available
Ventricular tachycardia02.03.04.0100.000066%
Vertigo17.02.12.002; 04.04.01.003--
Vision blurred17.17.01.010; 06.02.06.007--
Vomiting07.01.07.003--
Weight increased13.15.01.006--
Wheezing22.03.01.0090.000066%
Mental status changes19.07.01.0010.000295%Not Available
Cardiotoxicity12.03.01.007; 02.01.01.0020.000066%Not Available
Balance disorder17.02.02.0070.000066%Not Available
Deep vein thrombosis24.01.02.0030.000197%Not Available
Acute coronary syndrome24.04.04.011; 02.02.02.015--Not Available
Musculoskeletal discomfort15.03.04.001--Not Available
Inappropriate antidiuretic hormone secretion14.05.07.001; 05.03.03.001--Not Available
QRS axis abnormal13.14.05.0260.000066%Not Available
Disturbance in sexual arousal19.08.04.003--Not Available
Decreased appetite14.03.01.005; 08.01.09.028--
Erectile dysfunction21.03.01.007; 19.08.04.001--
The 6th Page    First    Pre   6 7    Next   Last    Total 7 Pages